“Game-changing” osteoarthritis drug receives £675k funding from Innovate UK
pharmafile | February 19, 2019 | News story | Manufacturing and Production, Research and Development | AKL Research and Development, Innovate UK, osteoarthritis, pharma
A novel and potentially “game-changing” oral therapy for the treatment of osteoarthritis (OA) has received a £675,000 cash injection from Innovate UK.
The funding will help support the enactment of a clinical of study to evaluate the drug’s safety and efficacy, undertaken by a partnership of AKL Research and Development (AKLRD) and the University of Liverpool’s Clinical Trials Unit.
APPA, as the therapy is known, consists of two synergistic phytochemicals and has demonstrated “significant” pain relief properties, slowed cartilage destruction, and improved functionality in preclinical animal trials.
The treatment is currently at Phase 1 in development, but the new grant will help push the drug into Phase 2 later this year, the partnership said.
“For APPA to be recognised as a disruptive innovation is incredibly exciting,” remarked David Miles, Chief Executive Officer of AKLRD. “The award from Innovate UK will allow us to secure the future development of what we believe could be an important medicine for OA patients who currently have limited treatment options. We believe APPA not only tackles pain but will also put the brakes on the inflammatory cascade that we know is responsible for the devastating consequences of OA.”
Professor Moots, of the UoL’s Institute of Ageing and Chronic Disease and leader of the APPA trial, commented: “Millions of osteoarthritis patients are suffering every day with severe pain because the current prescription drugs available are often not effective or cannot be used long-term. APPA has the potential to be an effective treatment for OA that could not only tackle the pain it causes but do so with excellent tolerability and also, we hope, stop the disease from causing further joint damage. It’s incredibly exciting that Innovate UK has clearly recognised the potential of this new drug which could transform the lives of OA patients.”
Matt Fellows
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Major funding opportunity opens for early cancer diagnostics
Up to £25.4m in funding is available for collaborative projects developing technologies to improve the …
